Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 121 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Streptococcus Pneumoniae Infection Clear all

Conditions: Pneumococcal Vaccines
Interventions: 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 45
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more

Conditions: Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: V114, Prevnar 13™; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 2,340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more

Conditions: Pneumococcal Infection
Interventions: V110, V114, mRNA-1273, Placebo for V110, Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 42
States / cities: North Hollywood, California • Northridge, California • Paramount, California + 38 more

Conditions: Study is Open to Seniors Age 50 or Older
Interventions: Pharmacist Pneumococcal Vaccine Program (PPVP); Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 50 Years and older
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: AFX3772, Prevnar 13, Prevnar 20; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more

Conditions: Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions: Colistimethate sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: Pneumococcal Disease
Interventions: Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC), Licensed pneumococcal comparator vaccine, Multivalent Pneumococcal Vaccine - Formulation 3, Multivalent Pneumococcal Vaccine - Formulation 4; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 17
States / cities: Doral, Florida • Miami Lakes, Florida • Stockbridge, Georgia + 12 more

Conditions: Pneumococcal Infection
Interventions: V116, Placebo, PCV15, PPSV23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 518 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more

Conditions: Pneumococcal Disease
Interventions: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 1,511 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 41
States / cities: Tucson, Arizona • Fullerton, California • Oxnard, California + 33 more

Conditions: Pneumococcal Vaccine
Interventions: MVX01, MVX01 Placebo; Biological
Lead sponsor: Matrivax Research and Development Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Savannah, Georgia • Knoxville, Tennessee

Conditions: Pneumonia, Pneumococcal
Interventions: V116, Pneumovax™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions: Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo; Biological · Drug
Lead sponsor: Serum Life Science Europe GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Infections, Streptococcal
Interventions: Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13®, PedvaxHIB®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,806 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Chinle, Arizona • Fort Defiance, Arizona • Whiteriver, Arizona + 2 more

Conditions: Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Interventions: Urine sample collection; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more

Conditions: Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
Interventions: ASP3772, PCV13, PPSV23; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Banning, California • San Diego, California • San Marcos, California + 21 more

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 2,409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Downey, California • Huntington Beach, California • San Diego, California + 18 more

Conditions: Pneumococcal Infection
Interventions: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 55 Years to 74 Years
Enrollment: 884 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 7
States / cities: Decatur, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more

Conditions: Pneumococcal Disease
Interventions: Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control, 13vPnC, PCV15; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 18
States / cities: Tustin, California • Walnut Creek, California • Milford, Connecticut + 12 more

Conditions: Pneumococcal Disease
Interventions: No Intervention; Other
Lead sponsor: Pfizer; Industry
Eligibility: 2 Months to 3 Years
Enrollment: 53,902 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Pneumococcal Disease
Interventions: 20vPnC, 13vPnC, PPSV23, Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,902 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more

Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 249 Days to 305 Days
Enrollment: 1,128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 39
States / cities: Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more

Conditions: Pneumococcal Disease
Interventions: 20vPnC, 13vPnC; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 21
States / cities: Anaheim, California • Sacramento, California • San Jose, California + 16 more

Conditions: Pneumococcal Infections
Interventions: Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 652 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 15
States / cities: Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more

Search by objective public record fields.

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Aerosolized and Intravenous Colistin in Healthy Adults

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)